REGENT PACIFIC (00575): Launch of Accrua-Deep Longevity Consumer Digital Health Platform in the United States

REGENT PACIFIC (00575) announces that Deep Longevity, Inc., a wholly-owned subsidiary of the Company, and its subsidiaries (collectively, "Deep Longevity") will launch its consumer digital health and telemedicine platform Accrua ("Accrua") in the United States ("U.S.") in October 2026 (the "Launch"). Accrua will be available to consumers across all 50 U.S. states from the date of launch. As set out in the Company's 2026 interim results announcement dated 25 August 2026 and the 2026 interim report, this launch represents the culmination of Deep Longevity's strategy to scale in the U.S. market through direct-to-consumer ("D2C") digital telemedicine services. The Board considers Accrua to be a potentially transformative development for the Group and an important new future revenue stream that complements Deep Longevity's existing business-to-business ("B2B") model. Accrua offers simple, direct, online medical services led by U.S. licensed clinicians. At the core of the platform is Deep Longevity's proprietary, AI-generated BloodAge report, which uses routine blood tests to determine whether a consumer is a "fast ager" that is, someone whose biological age is advancing faster than their chronological age. Following clinician consultation, Accrua offers a range of physician-directed treatment options, including medications for weight loss (such as glucagon-like peptide-1 ("GLP-1") therapy), peptides, women's health (such as hormone replacement therapy) and men's health (such as testosterone therapy). In each case, the initial treatment plan and subsequent adjustments are personalised by licensed clinicians and based on the user's BloodAge report, rather than relying on self-reported symptoms or a single biomarker. Users remeasure their BloodAge quarterly, enabling users and their clinicians to track treatment efficacy based on objective, science-based measures of biological ageing rather than relying on symptoms or weight alone. Accrua is positioned around a simple idea "You know your age. Your blood knows better." offering quarterly biological age measurement, clinician-directed treatment plans and compounded therapies as a comprehensive longevity care programme, backed by peer-reviewed science. The platform's initial launch categories include weight loss, women's health and men's health, with more categories planned. Accrua extends Deep Longevity's deep learning ageing clock technology and SenoClock platform directly to consumers for the first time, while continuing Deep Longevity's existing collaborations with clinics, hospitals, laboratories and insurers. The Board believes Accrua differentiates itself from other U.S. digital telemedicine platforms through the peer-reviewed, independent clinical research underpinning Deep Longevity's technology. Deep Longevity's BloodAge model was the subject of a peer-reviewed study by Goshen et al. published in Aging and Disease (2026), which followed approximately 2,600 adults for a mean of 9.2 years; after adjusting for age, sex, body mass index ("BMI"), smoking and hypertension, each additional year of gap between biological age and chronological age was independently associated with a 15% increase in mortality risk and a 6% increase in hospitalisation risk, with the association being independent. Deep Longevity's technology has also received significant external recognition, most recently being named runner-up in the Nestl VITAL Smart Ageing Global Challenge, a global innovation competition that attracted 150 companies worldwide. Accrua is entering the U.S. consumer digital health market, where platforms focused on related health and wellness areas have already achieved substantial revenue. For example, according to The New York Times (2 April 2026), MEDVi, LLC, a U.S. digital telemedicine platform focused on GLP-1 weight loss and related therapies, generated over US$400 million in revenue in 2025 (its first full year of operation), and on current trends its annualised revenue for 2026 could reach approximately US$1.8 billion (Forbes, 2 April 2026, citing The New York Times). Accrua covers a similar range of product categories. While there can be no assurance that Accrua will achieve comparable results, the Board believes these figures illustrate the scale of consumer demand and revenue potential in the market Accrua is targeting. Accrua is built on a capital-efficient model. Clinical service delivery will be provided by existing U.S. telemedicine infrastructure partners through networks of independently licensed physicians, pharmacies and compounding partners, covering clinician consultations, prescribing, pharmacy dispensing and delivery, patient enrolment and patient portals, electronic health records, billing and payment processing, secure video consultations and patient communications, across all 50 U.S. states. This model enables Deep Longevity to scale nationwide from the launch date without owning clinical infrastructure or directly bearing drug inventory. Revenue is expected to come primarily from subscriptions and to be recurring in nature. The launch will be supported by targeted digital marketing campaigns, initially focused on selected U.S. states, with the aim of optimising customer acquisition effectiveness before further scaling the business. The Board is deeply excited about the launch of Accrua. Accrua brings together Deep Longevity's world-class ageing clock technology, peer-reviewed independent scientific research and a proven, scalable telemedicine service delivery model to enter one of the largest and fastest-growing categories in the U.S. consumer healthcare market. The Board believes Accrua has the potential to become an important driver of the Group's revenue growth and to create meaningful long-term value for shareholders, and the Board looks forward to updating shareholders on Accrua's progress following its launch. Mr. Jamie Gibson, Executive Director and Chief Executive Officer of the Company, said, "The launch of Accrua is a milestone moment for Deep Longevity and the Group. For the first time, consumers across the United States will have direct access to our BloodAge science and to personalised care delivered by licensed clinicians. We believe that using biological age, rather than symptoms alone, as the basis for treatment is a genuinely new proposition in a market that has already demonstrated extraordinary consumer demand, and we are excited about the opportunities ahead."